1. Home
  2. MLYS vs CCNE Comparison

MLYS vs CCNE Comparison

Compare MLYS & CCNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MLYS
  • CCNE
  • Stock Information
  • Founded
  • MLYS 2019
  • CCNE 1865
  • Country
  • MLYS United States
  • CCNE United States
  • Employees
  • MLYS N/A
  • CCNE N/A
  • Industry
  • MLYS Biotechnology: Pharmaceutical Preparations
  • CCNE Major Banks
  • Sector
  • MLYS Health Care
  • CCNE Finance
  • Exchange
  • MLYS Nasdaq
  • CCNE Nasdaq
  • Market Cap
  • MLYS 526.1M
  • CCNE 595.8M
  • IPO Year
  • MLYS 2023
  • CCNE N/A
  • Fundamental
  • Price
  • MLYS $10.86
  • CCNE $25.67
  • Analyst Decision
  • MLYS Strong Buy
  • CCNE Hold
  • Analyst Count
  • MLYS 2
  • CCNE 1
  • Target Price
  • MLYS $30.00
  • CCNE $28.00
  • AVG Volume (30 Days)
  • MLYS 263.5K
  • CCNE 107.8K
  • Earning Date
  • MLYS 03-20-2025
  • CCNE 01-28-2025
  • Dividend Yield
  • MLYS N/A
  • CCNE 2.83%
  • EPS Growth
  • MLYS N/A
  • CCNE N/A
  • EPS
  • MLYS N/A
  • CCNE 2.39
  • Revenue
  • MLYS N/A
  • CCNE $217,361,000.00
  • Revenue This Year
  • MLYS N/A
  • CCNE N/A
  • Revenue Next Year
  • MLYS N/A
  • CCNE $17.74
  • P/E Ratio
  • MLYS N/A
  • CCNE $10.65
  • Revenue Growth
  • MLYS N/A
  • CCNE 0.09
  • 52 Week Low
  • MLYS $8.58
  • CCNE $17.74
  • 52 Week High
  • MLYS $16.91
  • CCNE $29.29
  • Technical
  • Relative Strength Index (RSI)
  • MLYS 51.57
  • CCNE 54.01
  • Support Level
  • MLYS $9.81
  • CCNE $24.32
  • Resistance Level
  • MLYS $10.79
  • CCNE $26.15
  • Average True Range (ATR)
  • MLYS 0.62
  • CCNE 0.78
  • MACD
  • MLYS 0.15
  • CCNE 0.16
  • Stochastic Oscillator
  • MLYS 100.00
  • CCNE 72.31

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking three or more antihypertensive medications typically including a diuretic.

About CCNE CNB Financial Corporation

CNB Financial Corp is providing integrated financial solutions, which create value for both consumers and businesses. These solutions encompass deposit accounts, private banking, real estate, commercial, industrial, residential and consumer loans and lines of credit, credit cards, treasury services, online banking, mobile banking, merchant credit card processing, remote deposit and accounts receivable handling. In addition, the corporation provides wealth and asset management services, retirement plans and other employee benefit plans.

Share on Social Networks: